X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

January 17, 2020

The Latest on Regulations: ICH Guideline to Manage Change throughout the Commercial Lifecycle of Drugs and Combination Products – Part 2

Part 1 of this two part blog series, gave a high-level overview of the new ICH guideline <em>Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management</em>.&nbsp; In part 2 of this blog series, some of the key takeaways will be discussed in more detail.&nbsp; <em>Q12</em> is intended to help companies demonstrate increased product and process knowledge, and understand which post-approval changes will require a regulatory submission, as well as the level of reporting for each category.
Fran DeGrazio

Fran DeGrazio

VP Scientific Affairs and Technical Services

Previous Posts
SmartDose Gen II Drug Delivery Platform

December 31, 2019

Combination Products: The Top Three Device Challenges

Jen Riter

Jen Riter

Sr. Director, Lab Services

SmartDose Platform

April 26, 2019

Overcoming Challenges Associated with Biologic Drug Formulation and Development

Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Introducing Integrated Solutions

October 08, 2018

Introducing Integrated Solutions

Deirdre Swinden

Deirdre Swinden

Director, Marketing Communications

The SmartDose Platform in use

August 10, 2018

Combination Products - Why Design Verification Studies Are Needed

Daniel Bantz

Daniel Bantz

Technical Manager, Packaging & Performance, Lab

SmartDose Platform

August 08, 2018

Performance Testing: Strategies to Qualify Combination Products

Page McAndrew

T. Page McAndrew, Ph.D.

Director, Scientific Communications, SA & TS

Mixject Admixture System

January 30, 2018

Co-Packaged Combination Products – System vs Component

Doug Hostetler

Doug Hostetler

Principle SME, Admin. Systems, TCS

Load more